Randomized Clinical Trial to Verify a Cost-effectiveness of the Standard Pharmacotherapy for Major Depressive Disorder

Randomized Clinical Trial to Verify a Cost-effectiveness of the Standard Pharmacotherapy for Major Depressive Disorder - Cost-effectiveness of the Pharmacotherapy for Major Depressive Disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013923

Enrollment

100

Registered

2014-07-01

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

escitalopram and aripiprazole escitalopram and mirtazapine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: major depressive disorder

Exclusion criteria

Exclusion criteria: Long QT, and so on

Design outcomes

Primary

Measure	Time frame
QIDS QALY cost	—

Secondary

Measure	Time frame
HAM-D CGI	—

Countries

Japan

Contacts

Public ContactKazuo Yamada

Tokyo Women's Medical University, Medical Center East Psychiatry

yamadaps@dnh.twmu.ac.jp03-3810-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026